🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Such a privilege to go to Prof Griffiths valedictory event yesterday - what a career! An inspiration to many who has transformed psoriasis treatment (the most cited author of papers on psoriasis in the world) and yet still always has time for people. Thank you Chris Griffiths

Hello Glasgow! Looking forward to Prof Sloan from Penny Lovat group presenting AMBLor today, a prognostic biomarker to identify low-risk AJCC stage I/II non-ulcerated melanomas. Come along 11:50am #dermtwitter #BAD2022 @HealthySkin4All

We have created a new guide which is designed to help patients decide whether adjuvant therapy is right for them. It covers information about targeted therapy and immunotherapy. The adjuvant therapy guide: buff.ly/3yXkm4V #melanoma #skincancer #skincancerawareness

Come check out our Poster 41 at The 19th International Congress of the Society for Melanoma Research! @societymelanoma ⁦AMLo Biosciences⁩ ⁦Penny Lovat ⁦Newcastle University ⁦⁦University of Sunderland⁩ #biomarker #translational #NorthEastSkinResearchFund #SMR2022 #Edinburgh

Claire Jones providing a great example of a successful research project collaboration with AMLo Biosciences #collaboration #biosciences #research #workingtogether #cancerresearch

Breaking news: The shortlist for our #IEAwards22 is here! Congratulations to everyone who made the shortlist, we can't wait to celebrate with you at our Awards Ceremony on 6 December! 🥂

Are current follow-up recommendations for melanoma patients adequate? Unfortunately this study found that evidence supporting current guidance is sparse. The use of a biomarker test #AMBLor could help direct appropriate follow up for melanoma patients. AMLo Biosciences

Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma academic.oup.com/bjd/article/do…

The programme features a visit to Newcastle University that, with funding from us, has developed a pioneering test which reliably predicts which people's early-stage melanomas are at low risk of recurring.  business.itn.co.uk/programmes/sha… AMLo Biosciences Penny Lovat

I’m thrilled to share our last findings on overcoming the challenges of targeted therapy in melanoma treatment published on PNAS pnas.org/doi/10.1073/pn… Huge thanks to all my team, especially Luca Di Leo 🤩and Corine Bertolotto FilomeniLab Pietro Berico Penny Lovat Melanoma Research

DeZio_Lab Corine Bertolotto FilomeniLab Pietro Berico Penny Lovat Melanoma Research Congrats ☺️

On #WorldCancerDay2025 read how our researchers have developed novel AI technology to determine the course & severity of aggressive skin cancers. This new technique is leading to enhanced clinical decision making & personalised treatments. ⬇️ ncl.ac.uk/press/articles… #WeAreNCL